NCT01001442 (Clinical Trial/ BT062 / Indatuximab ravtansine)

Study Title
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (NCT01001442)

Trial Description
This Phase I/II clinical study is to test safety and anti-tumor activity of BT062 (also known as Indatuximab Ravtansine) to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.

This trial is sponsored by Biotest Pharmaceuticals Corporation. [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • BT062 (Indatuximab ravtansine)
  • Phase: I & II
  • Estimated Enrollment: 70
  • Start: August 2010
  • Estimated Completion: March 2016
  • Last verified: January 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: September 29, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.